Teva moving from pure play generics to global pharma company, CEO says
ReutersJan 28, 2026 2:58 PM
JERUSALEM, Jan 28 (Reuters) - Teva Pharmaceutical Industries TEVA.TA was quickly moving from a pure-play generics drugmaker to a global biopharma company as its branded medicines continue to grow, CEO Richard Francis said on Wednesday after Teva issued fourth-quarter results.
Francis told Reuters that branded drug sales should reach $3.5 billion to $4 billion in 2027 and $10 billion after 2030.
Teva TEVA.N posted 2025 revenue of $17.3 billion, with $3.1 billion coming from a trio of branded drugs to treat Huntington's Disease, migraines and schizophrenia. It forecast revenue of up to $3.6 billion from the three treatments in 2026.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
Netflix After the Warner Deal: What Investors Should Know
TradingKey - For quite some time now, Netflix (NFLX) has been regarded as the premier subscription-based streaming service in the world, with a well-established history of growth through creative use of pricing power, developing hit programming, and relying very little on outside sources for licensiTradingKey
10 hours ago
Warsh’s Fed Era Signals a Death Knell for QE, Jolting the $30 Trillion Treasury Market
With Warsh’s nomination, his past proposals for governing the Federal Reserve are being brought to the forefront. A central issue is the formulation of a new "1951 Accord" to restructure the relationship between the Fed and the Treasury. Analysts suggest such a move could impact the $30 trillion TreTradingKey
Mon, Feb 9
Amazon Stock Predictions for 2026 to 2030: Will They Exceed Expectations and Achieve Major Long-Term Goals?
TradingKey - As we head into 2026, many investors are questioning where Amazon (AMZN) fits into the technology world.TradingKey
Fri, Feb 6
A Crash After a Surge: Why Silver Lost 40% in a Week?
TradingKey - Spot silver (XAGUSD) prices continue to decline. Silver plunged 20% on Thursday, breaking below $71 per ounce, with the sell-off intensifying on Friday as prices fell further below $64. Compared to the all-time high set on January 29, silver prices have retraced more than 40%, wiping out nearly all gains accumulated over the previous month.TradingKey
Fri, Feb 6
